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Abstract
Background: Hepatocellular carcinoma (HCC) is a particularly severe disease characterized by a high rate of
recurrence and death even after surgical resection. Molecular characterization of HCC helps refine prognosis and
may facilitate the development of improved therapy. Phosphatidylinositol 4-kinases have recently been identified as
cellular factors associated with cancer. Also, phosphatidylinositol 4-kinase type IIIα (PI4KA) is necessary for the
propagation of the hepatitis C virus, a major etiological factor for HCC.
Methods: Reverse transcription, quantitative real-time PCR was used to assay PI4KA mRNA. The expression levels
were investigated both in a collection of molecularly and clinically characterized hepatic tissues from 344 patients
with diverse liver diseases and in human hepatocyte cell lines whose proliferative and differentiation status was
controlled by specific culture conditions. Analytical microarray data for 60 HCC and six normal liver tissue samples
were exploited to study correlations between PI4KA mRNA levels and cell proliferation markers in vivo. Postoperative
disease-specific survival and time to recurrence in a set of 214 patients with HCC were studied by univariate and
multivariate analyses.
Results: PI4KA mRNA was more abundant in HCC than normal healthy tissues. This upregulation correlated
significantly with both poor differentiation and the active proliferation rate in HCC. These associations were
confirmed with in vitro models. Moreover, patients with HCC who had been treated by surgical resection and had
higher PI4KA mRNA concentrations in their tumor tissue exhibited a higher risk of tumor recurrence (median time:
20 months versus 49 months, P = 0.0012) and shorter disease-specific survival (first quartile time: 16 months versus
48 months, P = 0.0004). Finally, the abundance of PI4KA mRNA proved to be an independent prognostic marker of
survival for cases of HCC (hazard ratio = 2.36, P = 0.0064).
Conclusions: PI4KA mRNA could be used as a new molecular marker to improve established prognostic models for
HCC. These findings also indicate possible new lines of research for the development of innovative therapeutic
approaches targeting PI4KA.
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Background
Liver cancers are the third leading cause of death by can-
cer worldwide, and are the sixth most common group of
malignancies [1]. Hepatocellular carcinoma (HCC) is the
most common primary cancer of the liver (70-80%), more
frequent than cholangiocarcinoma, and is more frequent
in men than in women [2]. It rarely occurs in normal liver.
In western countries, HCC mostly affects patients already
suffering from cirrhosis due to chronic alcohol intake, or
to chronic hepatitis B virus (HBV) or hepatitis C virus
(HCV) infections [3]. Some cases of HCC emerge by
malignant transformation of hepatocellular adenomas
(HCA). HCA are benign hepatocellular tumors that de-
velop mostly in otherwise normal liver in women taking
oral contraception [4]. Classifications for HCA and HCC,
based on their molecular signatures, have been established
to refine prognosis and to facilitate work to develop tar-
geted therapies. Thus, a genotype/phenotype classification
identified five different molecular subgroups of HCA: (i)
hepatocyte nuclear factor 1 homeobox A (HNF1A) mu-
tated, (ii) inflammatory, (iii) catenin (cadherin-associated
protein) beta 1 (CTNNB1) mutated, (iv) inflammatory and
CTNNB1 mutated, and (v) unclassified. The presence of
mutations in the CTNNB1 gene is a factor for poor prog-
nosis, as they are associated with a high risk of malignant
transformation of HCA to HCC [5,6]. Several transcrip-
tomic classifications of HCC provide evidence of the sub-
stantial genetic and phenotypic heterogeneity of this
tumor type [7]. One of these classifications individualizes
six molecular subgroups (G1 to G6) related to clinical and
pathological features [8]. However, the mechanisms
underlying the molecular and phenotypic differences be-
tween HCCs remain to be deciphered.
There has been growing interest in phosphatidylinositol
4-kinase type IIIα (PI4KA) and its involvement in liver
disease. We and others have shown that this enzyme
is required for the propagation of HCV, one of the
main etiological factors of HCC [9-13]. Four different
phosphatidylinositol 4-kinases (PI4Ks) are expressed in
human cells [14]. These isoenzymes (PI4KA, PI4KB,
PI4K2A and PI4K2B) catalyze the phosphorylation of
phosphatidylinositol (PtdIns) in the cytoplasmic face of
cellular membranes, leading to the production of phos-
phatidylinositol 4-phosphate (PtdIns4P). Each isozyme
displays a specific subcellular distribution. Thus, PI4KA is
mainly found in the endoplasmic reticulum (ER). Its activ-
ity seems to regulate both the formation of ER exit sites
[15,16] and the concentration of PtdIns4P in the plasma
membrane [17]. PtdIns4P is a precursor of other phos-
phoinositides (PIs), generated by additional phosphoryl-
ation(s), involved in a wide range of cellular functions
[18]. For example, cell migration and proliferation are
controlled by PI-dependent signaling pathways involving
phospholipase C (PLC) isozymes or phosphoinositide 3-
kinases. Therefore, it is unsurprising that some cancers
are associated with various types of deregulation in these
signaling pathways, including those affecting PI4Ks [19].
The analysis of PI4KA expression in various liver dis-
eases may therefore be informative. It may improve the
molecular characterization of HCC, providing diagnostic
and prognostic tools, and may even be useful to adapt
and improve therapy. Moreover, the importance of
PI4KA to the HCV life cycle makes it a potential thera-
peutic target. However, any treatment targeting PI4KA
may be affected by its expression. In this context, we in-
vestigated PI4KA expression in large cohort of liver dis-
eases. Because antibodies suitable for the detection of
the endogenous protein by immunohistochemistry are
not available, we used quantitative RT-PCR to assay
PI4KA mRNA. We found that the PI4KA gene was more
strongly expressed in HCC than in normal liver. This ex-
pression was correlated with the differentiation status.
PI4KA also appeared to be an independent marker of an
unfavorable prognosis in HCC.
Methods
Biological materials
All patients gave written consent as required by French
law. This study was approved by our local IRB commit-
tees (CCPRB for “Comité Consultatif de Protection des
Personnes dans la Recherche Biomédicale” Paris Saint
Louis and CPP for “Comité de Protection des Personnes”
Ouest V). Liver tissues were collected in French hospi-
tals and immediately frozen in liquid nitrogen after sur-
gical resection. The first library included a total of 344
liver samples with five normal and 339 pathological tis-
sues (21 cirrhosis, 101 HCA and 217 HCC). Two add-
itional normal tissue samples were used as calibrators
for the relative levels of transcripts in samples as deter-
mined by quantitative RT-PCR. The molecular subtype
of each of the 101 HCA (see Additional file 1 for clinical
and molecular features) was determined according to an
established molecular classification using gene mutation
and immunohistochemistry staining [4-6]. The set of
217 HCC included in this study has already been exten-
sively described (the main clinical, pathological and mo-
lecular features are presented in Additional file 2) [20].
All HCC were screened for TP53 and CTNNB1 muta-
tions and were classified using the G1-G6 molecular
classification as previously described [8,21]. The second
cohort consisted of liver fragments from 31 patients who
underwent surgical resection for hepatic metastases;
these fragments were taken in macroscopically normal
liver at a distance from the metastasis.
Huh-7.5.1 and HepaRG cell cultures were maintained
as previously described and were subjected to specific
differentiation protocols [22,23]. Huh-7.5.1 cells were
seeded at a density of 6 × 104 per cm2 in standard
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medium, consisting of complete DMEM (Life Technolo-
gies) supplemented with 100 U/ml penicillin (Life Tech-
nologies), 100 μg/ml streptomycin (Life Technologies),
2 mM L-glutamine (Life Technologies), 10 mM HEPES
(Life Technologies), nonessential amino acids (Sigma-
Aldrich) and 10% heat-inactivated fetal bovine serum
(Hyclone, Logan, UT, USA). When the culture reached
95% confluence, defined as day 0 (D0), the standard
culture medium was supplemented with 1% dimethyl
sulfoxide (DMSO, Sigma-Aldrich) for 6 consecutive
days. Cells were collected on days 0, 1, 3 and 6 (D0, D1,
D3 and D6, respectively). HepaRG cells were seeded at
a density of 2.7 x 104 per cm2 on day 0 and maintained
for two weeks in William’s E medium (Life Technolo-
gies) supplemented with 100 U/ml penicillin (Life
Technologies), 100 μg/ml streptomycin (Life Technolo-
gies), 5 μg/ml insulin (Sigma-Aldrich), 50 μM hydro-
cortisone hemisuccinate (Roussel) and 10% fetal bovine
serum (Hyclone, Logan, UT, USA). Then, the culture
medium was or was not supplemented with 2% DMSO
(Sigma-Aldrich) for two additional weeks. Cells were
collected at days 4, 15 and 30 post-seeding (D4, D15
and D30, respectively). D30- and D30+ indicate that
cells were cultured without DMSO for 30 days or with-
out DMSO for 15 days and then with 2% DMSO for
15 days, respectively.
Quantitative RT-PCR and microarray analysis
DNA and RNA were purified with commercial kits
(Qiagen). Quantitative RT-PCR and its data analysis
were performed as previously described [24]. TaqMan
gene expression assays (hs99999901_s1 and hs01021084m1,
Applied Biosystems) were used to analyze 18S and PI4KA
expression, respectively. The last assay detected both PI4KA
mRNA variants referenced in GenBank (NM_058004.3 =
Variant 1, NM_002650.2 = Variant 2) with no amplifica-
tion of pseudogene products. The probe hybridizes at
the exon-exon junctions 39–40 and 7–8 of variants 1
and 2, respectively. For absolute quantification, a plas-
mid (pCMV-SPORT6-hPI4KA, Open Biosystems) con-
taining the PI4KA cDNA (BC018120) was used for
calibration. The sequences of the other primers used
are given in Additional file 3. The microarray data (60
HCC and 6 normal livers) have been extensively de-
scribed previously [8] and are available on a public
database (E-TABM-36).
Statistics
Continuous data were compared using the non-parametric
Mann–Whitney Test (two groups) or Kruskal-Wallis Test
(more than two groups). Spearman or Pearson tests were
used for correlation analysis according to sample size. We
used the Mantel Cox log rank test and Kaplan Meier
method to assess post-resection survival. Disease-specific
survival is defined by the tumor-related death and patients
who died of another etiology were censored. Recurrence-
free survival was defined as the length of time after hepa-
tectomy for HCC during which a patient survives with no
sign of HCC. The last recorded follow-up visit was in
February 2011. Univariate analysis using Cox models
was performed to identify variables associated with
disease-specific survival. Variables with a P value < 0.05
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Figure 1 PI4KA transcript abundance in human liver samples of various subtypes. Scatter plots show the PI4KA mRNA levels in human
liver tissues as assayed by RT-real time PCR. Values represent the gene expression of each sample relative to the mean value for two control
samples from normal hepatic tissues. The 18S RNA levels were used for normalization. Means with standard deviations are indicated for each
sample category. P values from Kruskal-Wallis tests (more than two groups, panels A and B; black line) or MannWhitney U-tests (two groups,
panel C; black line with arrows) are indicated. (A) Comparison between normal hepatic tissue (n = 5), cirrhotic tissue (n = 21), and benign (HCA,
n = 101) and malignant (HCC, n = 217) hepatocellular tumors. (B) Expression in different hepatocellular adenoma (HCA) groups subdivided into
adenomas inactivated for HNF1A (n = 27), inflammatory adenomas (n = 44), β-catenin-activated adenomas (n = 10), inflammatory and
β-catenin-activated adenomas (n = 13) and unclassified adenomas (n = 7). (C) Expression compared according to the differentiation grade of
HCC grouped according to the Edmonson classification (Grades I-II, n = 118; Grades III-IV, n = 88).
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in the univariate analysis were entered into a Cox
multivariate model. P values < 0.05 were considered as
significant. Statistical analysis was performed using
Graphpad Prism and R statistical software (http://www.
R-project.org/).
This study adheres to the REMARK guidelines [25].
Results and discussion
PI4KA transcript levels in pathological human livers
A liver tissue library of 344 characterized samples was
exploited to compare PI4KA transcript levels in normal
and various pathological hepatic tissues (Figure 1A).
There were no significant differences between normal
and cirrhosis samples. PI4KA mRNA was slightly more
abundant in HCA than in normal samples (1.4-fold;
Mann–Whitney test: P = 0.0235). We therefore tested
for differences between the different HCA subgroups
classified according to their specific pathomolecular
signature (Figure 1B) [4-6]. PI4KA mRNA levels were
higher in HCA with mutations in HNF1A gene than
other HCA subgroups. The HNF1A gene encodes the
hepatocyte nuclear factor 1-alpha, involved in hepatocyte
differentiation [26].
The level of PI4KA transcripts was 2.1 times higher
(Mann–Whitney test: P = 0.0023) in HCC than normal
reference samples (Figure 1A). The PI4KA mRNA values,
however, did not differ significantly between HCC from
patients with and without chronic HCV infection (data
not shown). This is consistent with the observation that
HCV promotes its replication by stimulating the activity
of PI4KA but not the expression of its gene [27].
Influence of differentiation/proliferative status of
cancerous liver cells on PI4KA transcript levels
The overexpression of PI4KA in HCC could not be ex-
plained by HNF1A mutations: the frequency of these
Huh7.5.1 HepaRG
p = 0.0052
p = 0.0052
Huh7.5.1 HepaRG
A B C
Figure 2 PI4KA mRNA in in vitro models according to their hepatic differentiation state. Determination by RT-real time PCR of copy
numbers of PI4KA transcripts in sub-confluent cultures of Huh-7.5.1 (n = 3) or HepaRG (n = 3) and in normal human liver tissues (n = 31)
(A). P values from MannWhitney U-tests are indicated. Huh-7.5.1 (B) and HepaRG (C) cell lines were subjected to specific differentiation protocols
over several days (see details in Methods section). PI4KA and hepato-specific (albumin and aldolase b) transcripts were assayed by RT-real time
PCR at the time points indicated, in three independent experiments. Results are expressed in amounts relative to those at the first time point. The
mRNA levels of the succinate dehydrogenase complex, subunit A (SDHA) were used for normalization. The top panels show the comparative
expression of PI4KA and albumin. The bottom panels present the correlations between PI4KA and albumin or aldolase B expression levels.
Spearmans rank order coefficients and P values are indicated above the graphs.
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mutations was low in our HCC series (<4%) [28]. By
contrast, the mutation of this hepatic differentiation fac-
tor was associated with upregulation of PI4KA mRNA in
HCA. We therefore looked for an association between
the differentiation state of HCC and amounts of the
PI4KA transcript. We found that the less differentiated
HCC, according to the Edmonson classification, showed
stronger PI4KA expression (compare grades I-II with
grades III-IV in Figure 1C).
To study the link between hepatic differentiation
and PI4KA mRNA level further, we used two well-
established in vitro models based on HCC derived cell
lines (Huh-7.5.1 derived from Huh-7 [23]; and HepaRG)
whose differentiation state can be controlled [22,29]. We
compared the absolute amounts of PI4KA mRNA in
Huh-7.5.1 cells, HepaRG cells and normal liver tissue.
Normal human hepatic specimens, from a cohort differ-
ent from that used in the analysis described above (pre-
sented in Figure 1), contained an average of 121.71 ±
28.59 PI4KA cDNA copies/ng of total RNA (Mean ±
SD); HepaRG and Huh-7.5.1 cells, both at proliferative
stages, had respectively 3.4-fold and 7.2-fold more
PI4KA transcripts (Figure 2A). Thus, as in HCC from
which these cell lines derive, a similar up-regulation of
PI4KA transcripts was detected. Furthermore, the quan-
tity of this mRNA was highest in the most dedifferen-
tiated cell line (Huh-7.5.1). By applying their specific
differentiation procedures, both cell lines gradually ac-
quired a more differentiated hepatocyte state, as evi-
denced by the up-regulation of the liver-specific ALDOB
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Figure 3 Correlation between PI4KA expression level, proliferative markers and molecular status of HCC. A correlation study between
PI4KA expression levels and PCNA or MKI67 expression levels was performed in 60 HCC and 6 normal liver tissues analyzed with the HG-U133A
Affymetrix GeneChip™ microarray. Pearsons rank order coefficients and P values are indicated for the correlations (A). Scatter plots show the
PI4KA mRNA as assayed by RT-real time PCR in HCC specimens stratified according to transcriptomic classification (G1-G3, n = 58; G4-G6, n = 149)
(B). Values represent the gene expression of each sample relative to the mean value for two control samples from normal hepatic tissues. The
18S RNA levels were used for normalization. Means with standard deviations are indicated for each sample category. The P value from a
MannWhitney U-test is indicated.
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Figure 4 Mantel-Cox survival curves. The Kaplan Meier method and Log-Rank test were applied to data for 214 patients with HCC classified
into two groups according to whether the PI4KA expression value was above or below the median (low- or high-amount of PI4KA mRNA). A and
B panels present disease-specific survival (tumor-related death) and tumor recurrence-free survival, respectively. P values are indicated. Numbers
at risk are indicated below each panel.
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gene encoding aldolase B and ALB gene encoding albu-
min. By contrast, the PI4KA transcripts levels gradually
decreased during differentiation (Figure 2B and C, top
panels). Spearman rank analysis showed that PI4KA
mRNA quantities in Huh-7.5.1 and HepaRG cells were
negatively correlated with the ALDOB and ALB mRNA
quantities (Figure 2B and C, bottom panels). Given that
the differentiated state of both cell lines is clearly associ-
ated with a decline in proliferative activity [29,30], our
data indicate that an increase in the number of PI4KA
transcripts correlates with hepatic dedifferentiation and
active proliferation.
High mitotic activity and proliferation rate are also fre-
quently associated with poor differentiation in cancer.
We therefore tested for a relationship between PI4KA
expression and two commonly used markers of cell pro-
liferation (proliferating cell nuclear antigen [PCNA] and
MKI67) in a series of 60 HCC and six normal liver tissue
samples analyzed with the HG-U133A Affymetrix Gene-
Chip™ microarray. PI4KA expression was partly but sig-
nificantly correlated with PCNA and MKI67 expression
in HCC (Figure 3A and B). This was corroborated by
the observation that the level of PI4KA mRNA was
higher in HCC classified in G1-G3 subgroups than in
HCC classified in G4-G6 subgroups (Figure 3B). In-
deed, the G1-G3 subgroups are known as the prolifera-
tive subclasses because they display transcriptomic
dysregulation of cell cycle genes [8,31]; they are also
typically enriched in poorly differentiated HCC (66%
of HCC in G1-G3 subgroups have an Edmonson
grade III-IV versus 35% of HCC in G4-G6 subgroups,
P = 0.0001, Fisher’s exact test), such as those carrying
TP53 mutations and those with high level of serum
AFP, both factors correlating with stronger expression
of PI4KA (Additional file 4). Thus, in vivo and in vitro
data sets were consistent and suggest that the quantity
of PI4KA transcripts is related to the differentiation
status and the proliferation rate of tumors.
While PI4K2A has been shown to be up-regulated in
at least seven types of human cancer [32], our work re-
ports for the first time a rise of PI4KA transcript levels
in a human carcinoma. The reason of this up-regulation
in HCC remains to be determined. However, studies
suggest that PI4KA may regulate signaling pathways in-
volved in survival and proliferation [19].
Prognostic significance of PI4KA transcript upregulation
The annotation of our HCC library includes clinical out-
comes, and in particular survival and recurrence data, so
we cross-checked these data with PI4KA mRNA expres-
sion levels. The 214 HCC samples were subdivided into
two groups with respectively low or high amounts of
PI4KA mRNA. These groups were stratified by the me-
dian value. Patients with highest rate of PI4KA mRNA
had shorter disease-specific survival: the first quartile of
time to tumor-related death was 16 months for HCC
with high PI4KA mRNA level, and 48 months for HCC
with low PI4KA mRNA level (p = 0.0004, Figure 4A).
Similar results were obtained for the risk of tumor re-
currence: medians time to tumor recurrence were
20 months for the group with the highest amounts of
PI4KA mRNA and 49 months for the other group of pa-
tients (p = 0.0012, Figure 4B). Multivariate analysis indi-
cated that high amount of PI4KA mRNA was associated
with disease specific survival (HR: 2.36 (1.27; 4.36), p =
0.006415), independently of classical clinical, biological
and pathological features such as size, number of tu-
mors, microvascular invasion, and tumor portal throm-
bosis (Table 1). This type of association between PI4KA
up-regulation and poor prognosis has been suggested by
comparisons of cancer cell lines derived from hamster
pancreas: PI4KA was more strongly expressed in the
most aggressive cell line [33]. PI4KA could therefore
serve as a prognostic marker, in addition to those
already identified, and may help improve the accuracy of
existing prediction models [20]. Further investigations
Table 1 Univariate and multivariate analysis of clinical, pathological and molecular variables for disease-specific
survival in 214 HCC
Univariate analysis Multivariate analysis
Variables HR 95% CI P HR 95% CI P
Cirrhosis 1.45 0.90-2.31 0.119 - - -
Multiple tumors 1.952 1.09-3.49 0.024 3.53 1.83-6.81 0.000167
HCC > 5 cm 1.705 1.04-2.80 0.035 1.88 1.01-3.47 0.044943
AFP > 20 ng/ml 2.04 1.25-3.32 0.0043 1.58 0.90-2.76 0.107818
Microvascular invasion 2.98 1.86-4.78 5.83e-06 1.98 1.09-3.60 0.024328
Tumor portal thrombosis 3.59 2.14-6.01 1.21e-06 1.92 1.01-3.66 0.045599
Differentiation: Edmonson III/IV 1.60 1.01-2.52 0.0436 0.88 0.50-1.54 0.653579
PI4KA high level 2.22 1.39-3.54 0.000823 2.36 1.27-4.36 0.006415
Bold values represent P values considered to be statistically significant (<0.05).
HR: hazard ratio; CI: confidence interval.
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are required to elucidate the role of this phospholipid
kinase in HCC and to assess whether it is a potential tar-
geted for therapy.
Conclusions
Our study clearly shows that PI4KA transcripts are more
abundant in HCC than normal liver tissue, and that this
upregulation is correlated to their differentiation/prolif-
eration status and is associated with poor survival. Fur-
ther work is needed to determine the involvement, if
any, of PI4KA in HCC pathogenesis.
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Additional file 1: Clinical and molecular features of hepatocellular
adenomas.
Additional file 2: Characteristics of 217 patients with hepatocellular
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Additional file 4: Correlation between PI4KA mRNA amount and
markers of HCC differentiation status. Scatter plots show the PI4KA
mRNA levels in HCC samples as assayed by RT-real time PCR. Values
represent the gene expression of each sample relative to the mean value
for two control samples from normal hepatic tissues. The 18S RNA levels
were used for normalization. Means with standard deviation are shown for
each sample category. P values from a Mann-Whitney U-test are indicated.
Expression according to TP53 mutation status (NM: not mutated, n = 175;
M: mutated, n = 40) (A) or to serum AFP level (AFP < 20 ng/ml, n = 109;
AFP > 24 ng/ml, n = 85) (B).
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